Aclaris Therapeutics Statistics
Share Statistics
Aclaris Therapeutics has 108.28M
shares outstanding. The number of shares has increased by 51.43%
in one year.
| Shares Outstanding | 108.28M |
| Shares Change (YoY) | 51.43% |
| Shares Change (QoQ) | 51.08% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 19 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 4.07M, so 3.76% of the outstanding
shares have been sold short.
| Short Interest | 4.07M |
| Short % of Shares Out | 3.76% |
| Short % of Float | 4.48% |
| Short Ratio (days to cover) | 4.26 |
Valuation Ratios
The PE ratio is -1.45 and the forward
PE ratio is -1.96.
Aclaris Therapeutics's PEG ratio is
-0.04.
| PE Ratio | -1.45 |
| Forward PE | -1.96 |
| PS Ratio | 10.24 |
| Forward PS | 1.7 |
| PB Ratio | 1.23 |
| P/FCF Ratio | -9.49 |
| PEG Ratio | -0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Aclaris Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.99,
with a Debt / Equity ratio of 0.
| Current Ratio | 3.99 |
| Quick Ratio | 3.99 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $306,885.25 |
| Profits Per Employee | $-2,165,000 |
| Employee Count | 61 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -2.29% in the
last 52 weeks. The beta is 0.43, so Aclaris Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.43 |
| 52-Week Price Change | -2.29% |
| 50-Day Moving Average | 1.52 |
| 200-Day Moving Average | 1.91 |
| Relative Strength Index (RSI) | 43.93 |
| Average Volume (20 Days) | 887,373 |
Income Statement
In the last 12 months, Aclaris Therapeutics had revenue of 18.72M
and earned -132.06M
in profits. Earnings per share was -1.71.
| Revenue | 18.72M |
| Gross Profit | 15.93M |
| Operating Income | -141.93M |
| Net Income | -132.06M |
| EBITDA | -51.72M |
| EBIT | -52.53M |
| Earnings Per Share (EPS) | -1.71 |
Full Income StatementBalance Sheet
The company has 24.57M in cash and 0 in
debt, giving a net cash position of 24.57M.
| Cash & Cash Equivalents | 24.57M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -902.86M |
| Total Assets | 220.33M |
| Working Capital | 94.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -20.07M
and capital expenditures -121K, giving a free cash flow of -20.2M.
| Operating Cash Flow | -20.07M |
| Capital Expenditures | -121K |
| Free Cash Flow | -20.2M |
| FCF Per Share | -0.26 |
Full Cash Flow StatementMargins
Gross margin is 85.09%, with operating and profit margins of -758.18% and -705.48%.
| Gross Margin | 85.09% |
| Operating Margin | -758.18% |
| Pretax Margin | -705.48% |
| Profit Margin | -705.48% |
| EBITDA Margin | -276.28% |
| EBIT Margin | -758.18% |
| FCF Margin | -107.88% |
